Migraine Management in Saudi Arabia: Expert Consensus Including CGRP Drugs

What the researchers found

Expert consensus from Saudi Arabia provides migraine management guidelines including positioning of anti-CGRP therapies within the local healthcare context.

Why it matters

These findings have significant implications for peptide-based therapeutic development and clinical practice.

The numbers in context

Expert consensus developed by Saudi neurologists reviewing international guidelines and local practice patterns.

How the study worked

Study design and methodology detailed in the full publication.

Who was studied

Expert consensus for migraine patients in Saudi Arabia

What this study cannot tell us

Study-specific limitations discussed in the full publication. Results should be interpreted within the context of study design.

How to read the evidence

Evidence assessment based on study design detailed in publication.

When this study was published

Published in 2025. Current peptide therapeutic research.

The bigger picture

This study contributes to the expanding understanding of how peptide-based therapeutics can be applied across medical specialties.

Questions still open

• What are the long-term implications?
• How do these results compare to existing evidence?
• What further research is needed?

Common questions

Read the original research

Migraine management in Saudi Arabia: An expert consensus.

Neurosciences (Riyadh, Saudi Arabia), 30(3), 169-176

Citation

Albilali, Abdulrazaq S; Alkawi, Ammar M; Alotaibi, Naser D; Qureshi, Shireen Am; Alabdali, Majed M; Alabdaly, Hani M; Alenzi, Bader A; Al Khathaami, Ali M; Elchami, Ziad M; Alesefir, Walid A. (2025). Migraine management in Saudi Arabia: An expert consensus.. Neurosciences (Riyadh, Saudi Arabia), 30(3), 169-176. https://doi.org/10.17712/nsj.2025.3.20240118